Trial Profile

Multicenter, Randomized, Controlled, Double-Masked Clinical Trial to Evaluate the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (The PEARL Study)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 23 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Simpinicline (Primary)
Indications Dry eyes
Focus Therapeutic Use
Acronyms PEARL
Sponsors Oyster Point Pharmaceuticals

Most Recent Events

11 Aug 2022 Results published in the Clinical Therapeutics
27 Apr 2022 According to an Oyster Point Pharmaceuticals media release, the integrated results from this study will be presented at the Association for Research in Vision and Ophthalmology (ARVO), 2022.
19 Apr 2022 According to an Oyster Point Pharmaceuticals data will be presented at the American Society of Cataract and Refractive Surgery (ASCRS).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com